Prospective clinical trials of venetoclax and hypomethylating agents for relapsed BPDCN by Naveen Pemmaraju, Luan Hai Phan, Geoffrey Fell, Marlise R. Luskin, Mahesh Swaminathan, Sherry Pierce, Courtney DiNardo, Abhishek Maiti, Marina Konopleva, Andrew A. Lane

Get full text

Overexpression of miR-125a in myelodysplastic syndrome CD34+ cells modulates NF-κB activation and enhances erythroid differentiation arrest. by Irene Gañán-Gómez, Yue Wei, Hui Yang, Sherry Pierce, Carlos Bueso-Ramos, George Calin, George Calin, María Del Carmen Boyano-Adánez, Guillermo García-Manero

Get full text

Impact of measurable residual disease clearance kinetics in patients with AML undergoing intensive chemotherapy by Wei-Ying Jen, Koji Sasaki, Farhad Ravandi, Tapan M. Kadia, Sa A. Wang, Wei Wang, Sanam Loghavi, Naval G. Daver, Courtney D. DiNardo, Ghayas C. Issa, Hussein A. Abbas, Cedric Nasnas, Alex Bataller, Samuel Urrutia, Omer S. Karrar, Sherry Pierce, Hagop M. Kantarjian, Nicholas J. Short

Get full text

A phase II trial of azacitidine with ipilimumab, nivolumab, or ipilimumab and nivolumab in previously untreated myelodysplastic syndrome by Ian M. Bouligny, Guillermo Montalban-Bravo, Koji Sasaki, Naval Daver, Elias Jabbour, Yesid Alvarado, Courtney D. DiNardo, Farhad Ravandi, Gautam Borthakur, Prithviraj Bose, Naveen Pemmaraju, Steven Kornblau, Tapan Kadia, Lucia Masarova, Koichi Takahashi, Michael Andreeff, Alexandre Bazinet, Hui Yang, Rashmi Kanagal-Shamanna, Chitra Hosing, Sherry Pierce, Meghan Meyer, Xuelin Huang, Guillermo Garcia-Manero

Get full text